Other

Neoplasm by Site

Non-malignant20,494 active trials253 approved drugs3,567 evidence items

NCIt: C3263
MeSH: D009371

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (4,275)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 301–325 of 4,275 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Revision and complication rates after total joint arthroplasty in patients with monoclonal gammopathy of undetermined significance and multiple myeloma.
Jacob D Kodra, Austen Schweinert, Abdullah A Memon et al. · Int Orthop · Oct 1, 2026 · PMID 42706455 · candidate dictionary pubmed
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.
Martin F Kaiser, Rachel H Phillip, Sarah R Brown et al. · Lancet Oncol · Oct 1, 2026 · PMID 42705255 · candidate dictionary pubmed
Sanguinarine chloride inducing ferroptosis and downregulating GPX4 expression in liver cancer: An integrated in silico, in vitro and in vivo study.
Wen Ouyang, Jianxin Gao, Jing Liu et al. · Exp Ther Med · Oct 1, 2026 · PMID 42683259 · candidate dictionary pubmed
Zirconium metal-organic framework-based composite drug delivery system for precise drug release and synergistic modulation of the tumor microenvironment in liver cancer therapy.
Yujia Han, Haixiang Zeng, Jing Xu et al. · Acta Biomater · Oct 1, 2026 · PMID 42692231 · candidate dictionary pubmed
Green synthesis of silver nanoparticle using Hemidesmus indicus (L) R. Br. root extract and cytotoxicity assessment against ovarian cancer cell line (SKOV3).
Jayachandran Halka, Gayathiri Gunasangkaran, Kumaresan Kowsalya et al. · Cytotechnology · Oct 1, 2026 · PMID 42676590 · candidate dictionary pubmed
[Expression of Concern] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.

Jing Guo, Li Chen, Ning Luo et al. · Oncol Rep · Oct 1, 2026 · PMID 42663282 · candidate dictionary pubmed

Characterization of B cell activation and spatial distribution in the tumor microenvironment of high-grade serous ovarian cancer.

Eleonora Capezzali, Martina Arcieri, Silvia Tonon et al. · Transl Oncol · Oct 1, 2026 · PMID 42660101 · candidate dictionary pubmed

LncRNA-driven alternative splicing landscapes associate with survival outcomes in ovarian cancer.

Yan Cao, Jian Zhao, Shan He et al. · Noncoding RNA Res · Oct 1, 2026 · PMID 42633203 · candidate dictionary pubmed

Integrative single-cell sequencing and machine learning analyses identify chronic inflammation and cancer-associated fibroblast subsets as drivers of adverse outcomes in ovarian cancer.

Mingqin Kuang, Changmei Shen, Chunping Yang et al. · Transl Oncol · Oct 1, 2026 · PMID 42632123 · candidate dictionary pubmed

NCAPD2 facilitates ovarian cancer progression via MYC-mediated unfolded protein response.

Guoying Cui, Hongqi Li, Yanqiu Wang et al. · Biochim Biophys Acta Mol Cell Res · Oct 1, 2026 · PMID 42586216 · candidate dictionary pubmed

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Ignace Vergote, David Cibula, Matthew Powell et al. · Lancet Oncol · Oct 1, 2026 · PMID 42705254 · candidate dictionary pubmed

Large Language Models Versus Multidisciplinary Tumor Board Decisions in Thyroid Cancer.

Bayram Barış Büyük, Arzu Or Koca, Felat Toprak et al. · Laryngoscope Investig Otolaryngol · Oct 1, 2026 · PMID 42689133 · candidate dictionary pubmed

CircRNA PVT1 promotes migration, invasion and glucose metabolism of thyroid cancer cells through modulating the miR-195-5p-PDK4 axis.

Huanli Hu, Yanan Lu, Yingchuan Sun et al. · Cytotechnology · Oct 1, 2026 · PMID 42597312 · candidate dictionary pubmed

OLR1 promotes cell proliferation and invasion while represses apoptosis via regulating histone H3 lysine 18 lactylation‑mediated LEMD1 in papillary thyroid cancer.

Jiawei Yu, Rui Pang, Bo Liu et al. · Oncol Rep · Oct 1, 2026 · PMID 42596831 · candidate dictionary pubmed

Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).

Jian Wang, Zhi Liu, Qing Zhang et al. · Int J Oncol · Oct 1, 2026 · PMID 42596830 · candidate dictionary pubmed

[Corrigendum] Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell‑like side population cells.

Dingjun Zhu, Xuesi Wan, Hai Huang et al. · Oncol Rep · Oct 1, 2026 · PMID 42596854 · candidate dictionary pubmed

Recommendation of the DEGRO Head and Neck Cancer Working Group: proton versus photon radiotherapy for oropharyngeal cancer in the context of contradictory phase III evidence.

Sabrina Reichl, Sebastian Adeberg, Simon Böke et al. · Strahlenther Onkol · Oct 1, 2026 · PMID 42706355 · candidate dictionary pubmed

Oncologic Outcomes in a Contemporary "PROTEUS-like" Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy.

Can Aydogdu, Benso John, Clara Seizer et al. · Eur Urol Open Sci · Oct 1, 2026 · PMID 42699359 · candidate dictionary pubmed

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

Shu Li, Chuanfan Zhong, Yixun Zhang et al. · Transl Oncol · Oct 1, 2026 · PMID 42685612 · candidate dictionary pubmed

Single-cell and spatial transcriptomic profiling identifies a fibroblast-like endothelial state and the MDK-NCL signaling axis in prostate cancer microenvironment remodeling.

Ruiang Wang, Yifan Li, Xiaoxiang Wang · Transl Oncol · Oct 1, 2026 · PMID 42669284 · candidate dictionary pubmed

Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.

Luca Russo, Ossian Longoria, Silvia Bottazzi et al. · Eur Urol Open Sci · Oct 1, 2026 · PMID 42668444 · candidate dictionary pubmed

Decoding the metabolic‑immune crosstalk: The role of glutamine and ammonium reprogramming in prostate cancer immune evasion (Review).

Peilong Wang, Xiaoran Li, Teng Ma et al. · Oncol Rep · Oct 1, 2026 · PMID 42663286 · candidate dictionary pubmed

Co-treatment with pyrvinium pamoate and hispidulin potently reduces stemness and promotes mitochondrial apoptosis in prostate cancer cells.

Riza Serttas, Suat Erdogan · Cytotechnology · Oct 1, 2026 · PMID 42643730 · candidate dictionary pubmed

[Retracted] 2',4'-dihydroxychalcone, a flavonoid isolated from Herba oxytropis, suppresses PC-3 human prostate cancer cell growth by induction of apoptosis.

Yuqing Sheng, Mingchang Zou, Yan Wang et al. · Oncol Lett · Oct 1, 2026 · PMID 42621497 · candidate dictionary pubmed

PCDHGB2 promotes docetaxel resistance in prostate cancer via TR4-mediated activation of the HIF-1α/VEGFA pathway.

Fanyu Meng, Xinyi Zhou, Yong Qin et al. · Cytotechnology · Oct 1, 2026 · PMID 42621174 · candidate dictionary pubmed